You are about to leave the Clinical Value website now.

Cancel

Biomarker

19 August 2024

Pioneering Innovations in HCC Detection for Enhance Patient Outcomes – Chang Gung Memorial Hospital

5 March 2024

Early-stage hepatocellular carcinoma screening in patients with chronic hepatitis B in China: a cost–effectiveness analysis

13 February 2024

The Pursuit for Better Patient Outcomes – Innovating HCC Management at Siriraj Hospital

18 September 2023

Advancing Liver Health Ecosystem for Improve Patient Outcomes: A Hong Kong Perspective

In this interview with Prof Yuen, Chief of Division of Gastroenterology and Hepatology in the University of Hong Kong, explore Hong Kong's current liver health ecosystem,…

READ MORE
23 August 2023

Building modern hepatocellular carcinoma surveillance programmes: taking steps to address a leading cause of liver cancer death in Asia

In this whitepaper, HCC surveillance programs in Asia were analysed. The learnings from well established HCC surveillance programs, as well as the challenges in areas that…

READ MORE
19 June 2023

Do combined assays of serum AFP, AFP-L3, DCP, GP73, and DKK-1 efficiently improve the clinical values of biomarkers in decision-making for hepatocellular carcinoma? A meta-analysis

This meta-analysis aims to provide insight on the efficacy of using combined biomarkers, AFP, AFP-L3, DCP, DKK-1, and GP73, for clinical decision-making for patients with HCC.…

READ MORE
19 May 2023

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

This guideline aims to adapt the ESMO 2017 guidelines to take into account potential differences related to ethnicity, cancer biology and standard practices associated with the…

READ MORE
19 May 2023

Expert Consensus Recommendations on Biomarker Testing in Metastatic and Non metastatic NSCLC in Asia

This report provides consensus recommendations for NSCLC biomarker testing from Asian lung cancer experts for clinicians working in Asia to improve patient care. Biomarker testing approaches…

READ MORE
19 May 2023

Hepatocellular carcinoma surveillance and the emerging role of biomarker-based models

A/Prof Simone Strasser recently published an independent commentary in the Australian Medical Research and Journal "Research Review", covering at length topics such as non-alcoholic liver disease…

READ MORE
19 April 2023

Clinical Utility of Protein Induced by Vitamin K Absence-II in Patients with Hepatocellular Carcinoma

This study aimed to assess the clinical utility of PIVKA-II in addition to AFP in patients with HCC. Bhatti ABHH, Naz K, Abbas G, Khan NY,…

READ MORE
17 March 2023

Evaluation of the diagnostic accuracy of des-gamma-carboxy prothrombin and alpha-fetoprotein alone or in combination for hepatocellular carcinoma: A systematic review and meta-analysis

This article aims to clarify the diagnostic value of DCP (PIVKA-II) and AFP in patients with different risk of HCC development (etiology, ethnicity, and various stages…

READ MORE
17 March 2023

A meta-analysis and of clinical values of 11 blood biomarkers, such as AFP, DCP, and GP73 for diagnosis of hepatocellular carcinoma

This study reanalyzes the related studies of 11 blood biomarkers of HCC, and compares the diagnostic value of these biomarkers for HCC systematically. Pang BY, Leng…

READ MORE
14 March 2023

Biomarkers for the Early Detection of Hepatocellular Carcinoma

This review highlights promising candidate biomarkers and biomarker panels that have completed phase II evaluation for the early detection of HCC. Parikh ND, Mehta AS, Singal…

READ MORE
14 March 2023

International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma

This white paper, which was developed by a group of experts in biomarker development, provides a framework on best practices to design, execute, and interpret biomarker…

READ MORE

Be the first to receive updates, event opportunities, and thought leadership insights.